Day One Biopharmaceuticals, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Day One Biopharmaceuticals, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Day One Biopharmaceuticals, Inc. do? Business model and key facts
Get the full picture of Day One Biopharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 181
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
Stocks related to Day One Biopharmaceuticals, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Day One Biopharmaceuticals, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Day One Biopharmaceuticals, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
